We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights The Howard Hughes, Wyndham Hotels & Resorts, Greif, CVR Energy and Avis Budget Group
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 14, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer Inc. (PFE - Free Report) , Raytheon Technologies Corp. (RTX - Free Report) , Diageo plc (DEO - Free Report) , Infosys Ltd. (INFY - Free Report) and Canadian Pacific Railway Ltd. (CP - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Pfizer, Raytheon and Diageo
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc., Raytheon Technologies Corp., and Diageo plc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Pfizer shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+34.7% vs. +17.6%). The company boasts a diversified portfolio of innovative drugs and vaccines including Ibrance and Prevnar. The zacks analyst believes that no company is as strongly placed in the COVID vaccines/treatment market as Pfizer right now.
Its COVID-19 vaccine has become a key contributor to the top line. The vaccine together with Pfizer's promising oral antiviral pill for COVID-19, Paxlovid is expected to generate a combined $54 billion in sales in 2022. Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth.
However, currency headwinds and pricing pressure are key top-line headwinds. Concerns remain about long-term growth drivers beyond its COVID-related products due to competitive pressure.
Raytheon Technologies shares have outperformed the Zacks Aerospace - Defense Equipment industry over the past year (+13.4% vs. -0.8%). The company continues to receive ample orders for its combat-proven defense products from the Pentagon. It expects both domestic and international program growth to boost its defense business.
Raytheon achieved $90 million of incremental merger synergies in the first quarter. Looking ahead, the company aims at achieving $335 million of incremental cost synergies during 2022. The stock holds a solid solvency position.
However, economic sanctions imposed by governments in response to Russia's invasion in Ukraine might hurt Raytheon. A comparative analysis of its trailing 12-month Price/Book ratio reflects a relatively gloomy picture. Purchase order declines, witnessed lately, with original equipment manufacturer customers delaying orders pose a risk to the stock.
Diageo shares have declined -9.6% over the past year against the Zacks Beverages - Alcohol industry's decline of -10.0%. The company is facing continued inflationary pressures and also currency headwinds are concerning. Nevertheless, margin growth was driven by supply productivity savings and price increases, which more than offset the higher cost inflation.
It provided a decent view for fiscal 2022, with organic sales momentum likely to continue in the second half of fiscal 2022. However, continued recovery in the on-trade channel, strong consumer demand in the off-trade and market share gains, which also aided the company's first-half fiscal 2022 performance.
The company witnessed sales, operating margin and earnings growth in first-half fiscal 2021 driven by organic sales growth across all regions. Strong recovery in gross margin and operating cost leverage along with higher marketing investments aided organic operating margin growth.
Other noteworthy reports we are featuring today include Infosys Ltd. and Canadian Pacific Railway Ltd.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights The Howard Hughes, Wyndham Hotels & Resorts, Greif, CVR Energy and Avis Budget Group
For Immediate Release
Chicago, IL – July 14, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer Inc. (PFE - Free Report) , Raytheon Technologies Corp. (RTX - Free Report) , Diageo plc (DEO - Free Report) , Infosys Ltd. (INFY - Free Report) and Canadian Pacific Railway Ltd. (CP - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Pfizer, Raytheon and Diageo
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc., Raytheon Technologies Corp., and Diageo plc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Pfizer shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+34.7% vs. +17.6%). The company boasts a diversified portfolio of innovative drugs and vaccines including Ibrance and Prevnar. The zacks analyst believes that no company is as strongly placed in the COVID vaccines/treatment market as Pfizer right now.
Its COVID-19 vaccine has become a key contributor to the top line. The vaccine together with Pfizer's promising oral antiviral pill for COVID-19, Paxlovid is expected to generate a combined $54 billion in sales in 2022. Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth.
However, currency headwinds and pricing pressure are key top-line headwinds. Concerns remain about long-term growth drivers beyond its COVID-related products due to competitive pressure.
(You can read the full research report on Pfizer here >>>)
Raytheon Technologies shares have outperformed the Zacks Aerospace - Defense Equipment industry over the past year (+13.4% vs. -0.8%). The company continues to receive ample orders for its combat-proven defense products from the Pentagon. It expects both domestic and international program growth to boost its defense business.
Raytheon achieved $90 million of incremental merger synergies in the first quarter. Looking ahead, the company aims at achieving $335 million of incremental cost synergies during 2022. The stock holds a solid solvency position.
However, economic sanctions imposed by governments in response to Russia's invasion in Ukraine might hurt Raytheon. A comparative analysis of its trailing 12-month Price/Book ratio reflects a relatively gloomy picture. Purchase order declines, witnessed lately, with original equipment manufacturer customers delaying orders pose a risk to the stock.
(You can read the full research report on Raytheon Technologies here >>>)
Diageo shares have declined -9.6% over the past year against the Zacks Beverages - Alcohol industry's decline of -10.0%. The company is facing continued inflationary pressures and also currency headwinds are concerning. Nevertheless, margin growth was driven by supply productivity savings and price increases, which more than offset the higher cost inflation.
It provided a decent view for fiscal 2022, with organic sales momentum likely to continue in the second half of fiscal 2022. However, continued recovery in the on-trade channel, strong consumer demand in the off-trade and market share gains, which also aided the company's first-half fiscal 2022 performance.
The company witnessed sales, operating margin and earnings growth in first-half fiscal 2021 driven by organic sales growth across all regions. Strong recovery in gross margin and operating cost leverage along with higher marketing investments aided organic operating margin growth.
(You can read the full research report on Diageo here >>>)
Other noteworthy reports we are featuring today include Infosys Ltd. and Canadian Pacific Railway Ltd.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.